N
TSVT

Natixis’s 2seventy bio TSVT Stock Holding History

Natixis’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,199
Closed -$851K – 1332
2021
Q4 		$851K Buy
+33,199
New +$1.04M ﹤0.01% 950

Other funds holding TSVT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Natixis's TSVT Position: Q1 2022 in Review

Natixis sold out of 2seventy bio (TSVT) in Q1 2022, closing a stake of 33,199 shares — an estimated $851K sold.

Natixis first reported a position in TSVT in Q4 2021 and held it in 1 quarter. The position peaked at $851K in Q4 2021. 133 funds tracked by Wall St. Rank hold TSVT as of Q1 2022.

  • Natixis reported no remaining 2seventy bio position as of Q1 2022 after selling out during the quarter.
  • Natixis sold 33,199 2seventy bio shares in Q1 2022, an estimated $851K.
  • Natixis first reported a position in 2seventy bio in Q4 2021 and held it in 1 quarter.
  • Natixis's 2seventy bio position peaked at $851K in Q4 2021.
  • 133 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.